172 related articles for article (PubMed ID: 10639386)
21. Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Murakami K; Fujioka T; Okimoto T; Sato R; Kodama M; Nasu M
Int J Antimicrob Agents; 2002 Jan; 19(1):67-70. PubMed ID: 11814770
[TBL] [Abstract][Full Text] [Related]
22. Effect of amoxicillin, clarithromycin, and rabeprazole, a new proton pump inhibitor, in eradication therapy for relapsing peptic ulcer diseases with Helicobacter pylori infection.
Hizawa K; Nakahara T; Yano Y; Inuzuka S; Akagi K; Matsumoto T
J Clin Gastroenterol; 2000 Dec; 31(4):338-9. PubMed ID: 11129280
[No Abstract] [Full Text] [Related]
23. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Murakami K; Sato R; Okimoto T; Nasu M; Fujioka T; Kodama M; Kagawa J; Sato S; Abe H; Arita T
Aliment Pharmacol Ther; 2002 Nov; 16(11):1933-8. PubMed ID: 12390102
[TBL] [Abstract][Full Text] [Related]
24. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
25. Bacteriostatic and bactericidal activity of rabeprazole against Helicobacter pylori.
Garza-González E; Tijerina-Menchaca R; Pérez-Pérez GI; Bosques-Padilla FJ
J Chemother; 2004 Dec; 16(6):612-3. PubMed ID: 15700857
[No Abstract] [Full Text] [Related]
26. Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Hawkey CJ; Atherton JC; Treichel HC; Thjodleifsson B; Ravic M
Aliment Pharmacol Ther; 2003 Apr; 17(8):1065-74. PubMed ID: 12694089
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases.
Welage LS; Berardi RR
J Am Pharm Assoc (Wash); 2000; 40(1):52-62; quiz 121-3. PubMed ID: 10665250
[TBL] [Abstract][Full Text] [Related]
28. Bactericidal activity and synergy studies of proton pump inhibitors and antibiotics against Helicobacter pylori in vitro.
Midolo PD; Turnidge JD; Lambert JR
J Antimicrob Chemother; 1997 Mar; 39(3):331-7. PubMed ID: 9096182
[TBL] [Abstract][Full Text] [Related]
29. Antibacterial properties of lansoprazole alone and in combination with antimicrobial agents against Helicobacter pylori.
Nakao M
J Clin Gastroenterol; 1995; 20 Suppl 1():S32-7. PubMed ID: 7673612
[TBL] [Abstract][Full Text] [Related]
30. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Gambaro C; Bilardi C; Dulbecco P; Iiritano E; Zentilin P; Mansia C; Usai P; Vigneri S; Savarino V
Dig Liver Dis; 2003 Nov; 35(11):763-7. PubMed ID: 14674665
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Murakami K; Sato R; Okimoto T; Nasu M; Fujioka T; Kodama M; Kagawa J
Aliment Pharmacol Ther; 2003 Jan; 17(1):119-23. PubMed ID: 12492740
[TBL] [Abstract][Full Text] [Related]
32. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism.
Miyoshi M; Mizuno M; Ishiki K; Nagahara Y; Maga T; Torigoe T; Nasu J; Okada H; Yokota K; Oguma K; Tsuji T
J Gastroenterol Hepatol; 2001 Jul; 16(7):723-8. PubMed ID: 11446878
[TBL] [Abstract][Full Text] [Related]
33. Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Malizia T; Tejada M; Marchetti F; Favini P; Pizzarelli G; Campa M; Senesi S
J Antimicrob Chemother; 1998 Mar; 41 Suppl B():29-35. PubMed ID: 9579710
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
[TBL] [Abstract][Full Text] [Related]
35. Oxygen concentration influences proton pump inhibitor activity against Helicobacter pylori in vitro.
Midolo PD; Turnidge JD; Lambert JR; Bell JM
Antimicrob Agents Chemother; 1996 Jun; 40(6):1531-3. PubMed ID: 8726032
[TBL] [Abstract][Full Text] [Related]
36. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis.
Padol S; Yuan Y; Thabane M; Padol IT; Hunt RH
Am J Gastroenterol; 2006 Jul; 101(7):1467-75. PubMed ID: 16863547
[TBL] [Abstract][Full Text] [Related]
37. Rabeprazole treatment attenuated Helicobacter pylori-associated gastric mucosal lesion formation in Mongolian gerbils.
Suzuki H; Miyazawa M; Nagahashi S; Sato M; Bessho M; Nagata H; Miura S; Ishii H
J Gastroenterol Hepatol; 2003 Jul; 18(7):787-95. PubMed ID: 12795750
[TBL] [Abstract][Full Text] [Related]
38. Growth inhibitory and bactericidal activities of lansoprazole compared with those of omeprazole and pantoprazole against Helicobacter pylori.
Nakao M; Malfertheiner P
Helicobacter; 1998 Mar; 3(1):21-7. PubMed ID: 9546114
[TBL] [Abstract][Full Text] [Related]
39. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
[TBL] [Abstract][Full Text] [Related]
40. [Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors].
Hong EJ; Park DI; Oh SJ; Song MJ; Choi WH; Hong CH; Park JH; Kim HJ; Cho YK; Shon CI; Jeon WK; Kim BI
Korean J Gastroenterol; 2008 Aug; 52(2):80-5. PubMed ID: 19077498
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
